Meeting
2019 ASCO Annual Meeting
A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
Authors
Zahi Ibrahim Mitri
Oregon Health & Science University, Portland, OR
Zahi Ibrahim Mitri , Jacqueline Vuky , Kathleen A. Kemmer , Michael A. Savin , Swapnil Parmar , Annette Kolodzie Kolodzie , Brett Johnson , Rochelle Williams-Belizaire , Joe W. Gray , Gordon B. Mills
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT03801369
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS1111)
DOI
10.1200/JCO.2019.37.15_suppl.TPS1111
Abstract #
TPS1111
Poster Bd #
186b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
First Author: Sarah Sammons
Poster
2023 ASCO Annual Meeting
Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician’s choice systemic therapy in patients with breast cancer brain metastases.
First Author: Colette Shen
First Author: B.J. Rimel